Human Papillomavirus Infections - Pipeline Review, H2 2015

Date: September 23, 2015
Pages: 164
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HE6624F19D0EN
Leaflet:

Download PDF Leaflet

Human Papillomavirus Infections - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Human Papillomavirus Infections - Pipeline Review, H2 2015’, provides an overview of the Human Papillomavirus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Infections Overview
Therapeutics Development
Pipeline Products for Human Papillomavirus Infections - Overview
Pipeline Products for Human Papillomavirus Infections - Comparative Analysis
Human Papillomavirus Infections - Therapeutics under Development by Companies
Human Papillomavirus Infections - Therapeutics under Investigation by Universities/Institutes
Human Papillomavirus Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Human Papillomavirus Infections - Products under Development by Companies
Human Papillomavirus Infections - Products under Investigation by Universities/Institutes
Human Papillomavirus Infections - Companies Involved in Therapeutics Development
3M DRUG DELIVERY SYSTEMS
Admedus Ltd
Agilvax, Inc.
Astex Pharmaceuticals, Inc.
Beijing Minhai Biotechnology Co., Ltd
Bharat Biotech International Limited
Biogenomics Limited
BioMAS Ltd.
Biota Pharmaceuticals, Inc.
Chongqing Zhifei Biological Products Co., Ltd.
Crucell N.V.
EpiPharm AG
FluGen, Inc.
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Genticel S.A.
Helix BioPharma Corp.
Immunservice GmbH
Indian Immunologicals Limited
Kaketsuken K.K.
LEO Pharma A/S
MediGene AG
NanoViricides, Inc.
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Organic Vaccines
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Zerun Biotechnology Co., Ltd.
Spider Biotech
Starpharma Holdings Limited
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited
Human Papillomavirus Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(digoxin + furosemide) - Drug Profile
854-A - DRUG PROFILE
ABI-1968 - Drug Profile
aminolevulinic acid hydrochloride - Drug Profile
AS-101 - Drug Profile
Aspidasept - Drug Profile
astodrimer - Drug Profile
AX-03 - Drug Profile
BTA-074 - Drug Profile
Candida Albicans Antigen - Drug Profile
Cell Therapy for Human Papillomavirus Infection - Drug Profile
DFD-05 - Drug Profile
diphencyprone - Drug Profile
EPI-N06 - Drug Profile
GTL-002 - Drug Profile
Herpecide - Drug Profile
HPV virus like particle vaccine - Drug Profile
human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile
human papilloma virus [types 16 and 18] vaccine - Drug Profile
human papilloma virus [types 16, 18] (bivalent) virus like particle vaccine - Drug Profile
human papilloma virus vaccine - Drug Profile
human papilloma virus vaccine - Drug Profile
human papillomavirus (tetravalent) vaccine - Drug Profile
human papillomavirus [serotypes 16, 31] virus like particle vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
hydrogen peroxide - Drug Profile
imiquimod - Drug Profile
ingenol mebutate - Drug Profile
interferon alfa-2b (recombinant) - Drug Profile
interferon alpha-2b (recombinant) - Drug Profile
ISANIL-01 - Drug Profile
LFX-453 - Drug Profile
NTP-01 - Drug Profile
NVN-1000 - Drug Profile
onalespib - Drug Profile
PL-202 - Drug Profile
PP-210 - Drug Profile
ProCervix - Drug Profile
ranpirnase - Drug Profile
RKP-00156 - Drug Profile
SB-105A10 - Drug Profile
SB-206 - Drug Profile
sinecatechins - Drug Profile
Small Molecules for HPV Infections - Drug Profile
SRT-100 - Drug Profile
Synthetic Peptides for Viral Infections - Drug Profile
Vaccine for Cervical Cancer and Genital Warts - Drug Profile
Human Papillomavirus Infections - Recent Pipeline Updates
Human Papillomavirus Infections - Dormant Projects
Human Papillomavirus Infections - Discontinued Products
Human Papillomavirus Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Human Papillomavirus Infections, H2 2015
Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Human Papillomavirus Infections - Pipeline by 3M Drug Delivery Systems, H2 2015
Human Papillomavirus Infections - Pipeline by Admedus Ltd, H2 2015
Human Papillomavirus Infections - Pipeline by Agilvax, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
Human Papillomavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2015
Human Papillomavirus Infections - Pipeline by Biogenomics Limited, H2 2015
Human Papillomavirus Infections - Pipeline by BioMAS Ltd., H2 2015
Human Papillomavirus Infections - Pipeline by Biota Pharmaceuticals, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015
Human Papillomavirus Infections - Pipeline by Crucell N.V., H2 2015
Human Papillomavirus Infections - Pipeline by EpiPharm AG, H2 2015
Human Papillomavirus Infections - Pipeline by FluGen, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Human Papillomavirus Infections - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
Human Papillomavirus Infections - Pipeline by Genticel S.A., H2 2015
Human Papillomavirus Infections - Pipeline by Helix BioPharma Corp., H2 2015
Human Papillomavirus Infections - Pipeline by Immunservice GmbH, H2 2015
Human Papillomavirus Infections - Pipeline by Indian Immunologicals Limited, H2 2015
Human Papillomavirus Infections - Pipeline by Kaketsuken K.K., H2 2015
Human Papillomavirus Infections - Pipeline by LEO Pharma A/S, H2 2015
Human Papillomavirus Infections - Pipeline by MediGene AG, H2 2015
Human Papillomavirus Infections - Pipeline by NanoViricides, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Nielsen Biosciences, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Novan, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Novartis AG, H2 2015
Human Papillomavirus Infections - Pipeline by Organic Vaccines, H2 2015
Human Papillomavirus Infections - Pipeline by Promius Pharma, LLC, H2 2015
Human Papillomavirus Infections - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Human Papillomavirus Infections - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015
Human Papillomavirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2015
Human Papillomavirus Infections - Pipeline by Spider Biotech, H2 2015
Human Papillomavirus Infections - Pipeline by Starpharma Holdings Limited, H2 2015
Human Papillomavirus Infections - Pipeline by Tamir Biotechnology, Inc., H2 2015
Human Papillomavirus Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Human Papillomavirus Infections Therapeutics - Recent Pipeline Updates, H2 2015
Human Papillomavirus Infections - Dormant Projects, H2 2015
Human Papillomavirus Infections - Dormant Projects (Contd..1), H2 2015
Human Papillomavirus Infections - Dormant Projects (Contd..2), H2 2015
Human Papillomavirus Infections - Dormant Projects (Contd..3), H2 2015
Human Papillomavirus Infections - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Human Papillomavirus Infections, H2 2015
Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3M Drug Delivery Systems
Admedus Ltd
Agilvax, Inc.
Astex Pharmaceuticals, Inc.
Beijing Minhai Biotechnology Co., Ltd
Bharat Biotech International Limited
Biogenomics Limited
BioMAS Ltd.
Biota Pharmaceuticals, Inc.
Chongqing Zhifei Biological Products Co., Ltd.
Crucell N.V.
EpiPharm AG
FluGen, Inc.
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Genticel S.A.
Helix BioPharma Corp.
Immunservice GmbH
Indian Immunologicals Limited
Kaketsuken K.K.
LEO Pharma A/S
MediGene AG
NanoViricides, Inc.
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Organic Vaccines
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Zerun Biotechnology Co., Ltd.
Spider Biotech
Starpharma Holdings Limited
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited
Skip to top


Influenza A Infections - Pipeline Review, H2 2014 US$ 1,500.00 Sep, 2014 · 141 pages

Ask Your Question

Human Papillomavirus Infections - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: